Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / NVSEF - Legend Biotech: Solid Traction With Carvykti Rollout

NVSEF - Legend Biotech: Solid Traction With Carvykti Rollout

Novartis Ag Basel Akt

2024-01-29 13:47:30 ET

Summary

  • Today, we take a look at Legend Biotech Corporation, a commercial-stage biopharmaceutical company focused on developing cell therapies for oncology and other indications.
  • The company has one approved product on the market, LCAR-B38M, for the treatment of multiple myeloma.  This product is a potential blockbuster and also known as Carvykti.
  • Most analyst firms are positive about Legend Biotech's prospects, with price targets ranging from $85 to $100 per share.
  • The company also inked a new licensing deal with Novartis in November.
  • An investment analysis of Legend Biotech Corporation follows in the paragraphs below.

Legends are best left as legends and attempts to make them real are rarely successful "? Michael Moorcock.

For further details see:

Legend Biotech: Solid Traction With Carvykti Rollout
Stock Information
Company Name: Novartis Ag Basel Akt
Stock Symbol: NVSEF
Market: OTC
Website: novartis.com
Menu
NVSEF NVSEF Quote NVSEF Short NVSEF News NVSEF Articles NVSEF Message Board
Get NVSEF Alerts

News, Short Squeeze, Breakout and More Instantly...